182 related articles for article (PubMed ID: 36810626)
21. Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma.
Martinez-Barbera JP; Andoniadou CL
Stem Cells; 2016 Feb; 34(2):268-76. PubMed ID: 26763580
[TBL] [Abstract][Full Text] [Related]
22. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
[TBL] [Abstract][Full Text] [Related]
23. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
[TBL] [Abstract][Full Text] [Related]
24. Pathology and pathogenesis of craniopharyngiomas.
Larkin SJ; Ansorge O
Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma.
Andoniadou CL; Gaston-Massuet C; Reddy R; Schneider RP; Blasco MA; Le Tissier P; Jacques TS; Pevny LH; Dattani MT; Martinez-Barbera JP
Acta Neuropathol; 2012 Aug; 124(2):259-71. PubMed ID: 22349813
[TBL] [Abstract][Full Text] [Related]
26. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
[TBL] [Abstract][Full Text] [Related]
27. Unicystic Ameloblastomatoid Cystic Craniopharyngioma: Pathological Discussion and Clinical Significance of Cyst Formation in Adamantinomatous Craniopharyngioma.
Okada T; Fujitsu K; Ichikawa T; Miyahara K; Tanino S; Niino H; Yagishita S
Pediatr Neurosurg; 2016; 51(3):158-63. PubMed ID: 26795029
[TBL] [Abstract][Full Text] [Related]
28. Common mutations of beta-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region.
Buslei R; Nolde M; Hofmann B; Meissner S; Eyupoglu IY; Siebzehnrübl F; Hahnen E; Kreutzer J; Fahlbusch R
Acta Neuropathol; 2005 Jun; 109(6):589-97. PubMed ID: 15891929
[TBL] [Abstract][Full Text] [Related]
29. Aberrant membranous expression of β-catenin predicts poor prognosis in patients with craniopharyngioma.
Li Z; Xu J; Huang S; You C
Ann Diagn Pathol; 2015 Dec; 19(6):403-8. PubMed ID: 26547438
[TBL] [Abstract][Full Text] [Related]
30. Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
Moreno-Torres B; Campos-Martín Y; Meléndez B; Garcia Martin RM; Vicente A; Rodríguez de Lope Á; Alen JF; Mollejo M; Hernández-Laín A
Clin Neuropathol; 2021; 40(1):26-35. PubMed ID: 33040839
[TBL] [Abstract][Full Text] [Related]
31. Pituitary adenoma, craniopharyngioma, and Rathke cleft cyst involving both intrasellar and suprasellar regions: differentiation using MRI.
Choi SH; Kwon BJ; Na DG; Kim JH; Han MH; Chang KH
Clin Radiol; 2007 May; 62(5):453-62. PubMed ID: 17398271
[TBL] [Abstract][Full Text] [Related]
32. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
[TBL] [Abstract][Full Text] [Related]
34. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
[TBL] [Abstract][Full Text] [Related]
35. CTNNB1 mutations are clonal in adamantinomatous craniopharyngioma.
Apps JR; Stache C; Gonzalez-Meljem JM; Gutteridge A; Chalker J; Jacques TS; Forshew T; Hölsken A; Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2020 Aug; 46(5):510-514. PubMed ID: 32125720
[No Abstract] [Full Text] [Related]
36. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
[TBL] [Abstract][Full Text] [Related]
37. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
Martinez-Barbera JP
J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515
[TBL] [Abstract][Full Text] [Related]
38. Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma.
Boult JKR; Apps JR; Hölsken A; Hutchinson JC; Carreno G; Danielson LS; Smith LM; Bäuerle T; Buslei R; Buchfelder M; Virasami AK; Koers A; Arthurs OJ; Jacques TS; Chesler L; Martinez-Barbera JP; Robinson SP
Brain Pathol; 2018 Jul; 28(4):475-483. PubMed ID: 28481062
[TBL] [Abstract][Full Text] [Related]
39. [Iconographic analysis for pituitary adenoma, craniopharyngioma and Rathke cleft cyst involving both intrasellar and suprasellar regions].
Song CQ; Ren XH; Sui DL; Lin S; Zhang Y
Zhonghua Yi Xue Za Zhi; 2013 Dec; 93(45):3610-3. PubMed ID: 24534313
[TBL] [Abstract][Full Text] [Related]
40. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
